Patents Assigned to AROVELLA THERAPEUTICS LIMITED
  • Use of anagrelide for treating cancer
    Patent number: 11324746
    Abstract: The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 10, 2022
    Assignee: AROVELLA THERAPEUTICS LIMITED
    Inventors: Stephen Damment, Richard Franklin, Jorge D. Erusalimsky